The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease
Open accessAbstract
OBJECTIVE: To characterize the shape of the trajectories of Alzheimer disease biomarkers as a function of Mini-Mental State Examination (MMSE) score. DESIGN AND SETTING: Longitudinal registries from the Mayo Clinic and the Alzheimer's Disease Neuroimaging Initiative. PATIENTS: Two different samples (n = 343 and n = 598) were created that spanned the cognitive spectrum from normal to Alzheimer disease dementia. Subgroup analyses were performed in members of both cohorts (n = 243 and n = 328) who were amyloid positive at baseline. MAIN OUTCOME MEASURES: The shape of biomarker trajectories as a function of MMSE score, adjusted for age, was modeled and described as baseline (cross-sectional) and within-subject longitudinal effects. Biomarkers evaluated were cerebrospinal fluid (CSF) Aβ42 and tau levels, amyloid and fluorodeoxyglucose positron emission tomography imaging, and structural magnetic resonance imaging. RESULTS: Baseline biomarker values generally worsened (ie, nonzero slope) with lower baseline MMSE score. Baseline hippocampal volume, amyloid positron emission tomography, and fluorodeoxyglucose positron emission tomography values plateaued (ie, nonlinear slope) with lower MMSE score in 1 or more analyses. Longitudinally, within-subject rates of biomarker change were associated with worsening MMSE score. Nonconstant within-subject rates (deceleration) of biomarker change were found in only 1 model. CONCLUSIONS: Biomarker trajectory shapes by MMSE score were complex and were affected by interactions with age and APOE status. Nonlinearity was found in several baseline effects models. Nonconstant within-subject rates of biomarker change were found in only 1 model, likely owing to limited within-subject longitudinal follow-up. Creating reliable models that describe the full trajectories of Alzheimer disease biomarkers will require significant additional longitudinal data in individual participants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“So far, biomarker studies demonstrated the successive development of primary pathologies including amyloid-β and tau (as measured by biofluid and molecular PET markers) followed by alterations of medial temporal and parietal grey matter (as measured by volumetric MRI and FDG-PET) in both sporadic late-onset Alzheimer’s disease (Jack et al., 2012) and genetically-caused Alzheimer’s disease (Bateman”
From White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s disease (2018) · cites this paper as Jack et al., 2012
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
A concordance correlation coefficient to evaluate reproducibility.
Lin, L. I.-K. (1989) · Biometrics · doi:10.2307/2532051 · Cited by 8,785
Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00569-x · Cited by 8,610
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationFitzmaurice, G. M., Laird, N. M., & Ware, J. H. (2011) · Wiley Series in Probability and Statistics · doi:10.1002/9781119513469 · Cited by 4,639
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
Self-citationCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationMild Cognitive Impairment: Ten Years Later
Petersen, R. C., Roberts, R. O., Knopman, D. S., Boeve, B. F., Geda, Y. E., Ivnik, R. J., Smith, G. E., & Jack, C. R. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.266 · Cited by 1,447
Self-citation
Research works printed but not linked: 2
- [10]Mintun MA Larossa GN Sheline YI [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease Neurology 2006 67 446 452 16894106
- [66]Sperling RA Aisen PS Beckett LA Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer Assocation Workgroup Alzheimers Dement 2011 PMC3220946 21514248
Cited by
Sorted by citations
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Self-citationBiomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002
Self-citationGordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30028-0 · Cited by 602
Self-citationBrain β-amyloid load approaches a plateau
Jack, C. R., Wiste, H. J., Lesnick, T. G., Weigand, S. D., Knopman, D. S., Vemuri, P., Pankratz, V. S., Senjem, M. L., Gunter, J. L., Mielke, M. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182840bbe · Cited by 406
Self-citationThe amyloid cascade hypothesis: are we poised for success or failure?
Karran, E., & De Strooper, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13632 · Cited by 402
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease
Benzinger, T. L. S., Blazey, T., Jack, C. R., Koeppe, R. A., Su, Y., Xiong, C., Raichle, M. E., Snyder, A. Z., Ances, B. M., Bateman, R. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317918110 · Cited by 391
Self-citationStructural imaging of hippocampal subfields in healthy aging and Alzheimer’s disease
de Florès, R., Joie, R. L., & Chételat, G. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.033 · Cited by 387
Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models
Bernal-Rusiel, J. L., Greve, D. N., Reuter, M., Fischl, B., & Sabuncu, M. R. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2012.10.065 · Cited by 360
Bron, E. E., Smits, M., van der Flier, W. M., Vrenken, H., Barkhof, F., Scheltens, P., Papma, J. M., Steketee, R. M. E., Méndez Orellana, C., Meijboom, R., et al. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.01.048 · Cited by 352
Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology
Schmitz, T. W., Spreng, R. N., Initiative, T. A. D. N., Weiner, M. W., Aisen, P. S. S., Petersen, R. C., Jack, C. R., Jagust, W. J., Trojanowki, J. Q., Toga, A. W., et al. (2016) · Nature Communications · doi:10.1038/ncomms13249 · Cited by 345
Self-citationVassar, R., Kuhn, P., Haass, C., Kennedy, M. E., Rajendran, L., Wong, P. C., & Lichtenthaler, S. F. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12715 · Cited by 311
Barthélemy, N. R., Bateman, R. J., Hirtz, C., Marin, P., Becher, F., Sato, C., Gabelle, A., & Lehmann, S. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00596-4 · Cited by 229
Magnetic resonance imaging in Alzheimer’s disease neuroimaging initiative 2
Jack, C. R., Barnes, J., Bernstein, M. A., Borowski, B. J., Brewer, J., Clegg, S., Dale, A. M., Carmichael, O., Ching, C., DeCarli, C., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.002 · Cited by 220
Self-citationIdiopathic REM sleep behaviour disorder in the development of Parkinson's disease
Boeve, B. F. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70054-1 · Cited by 211
Self-citationAmyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity
Jack, C. R., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Vemuri, P., Mielke, M. M., Jones, D. T., Senjem, M. L., Gunter, J. L., et al. (2013) · Neurology · doi:10.1212/01.wnl.0000435556.21319.e4 · Cited by 203
Self-citationRamanan, V. K., & Saykin, A. J. (2013) · Europe PMC (PubMed Central) · Cited by 190
Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease
Prestia, A., Caroli, A., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., Teunissen, C. E., Wall, A. E., Carter, S. F., Schöll, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182872830 · Cited by 184
White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s disease
Araque Caballero, M. Á., Suárez-Calvet, M., Duering, M., Franzmeier, N., Benzinger, T., Fagan, A. M., Bateman, R. J., Jack, C. R., Levin, J., Dichgans, M., et al. (2018) · Brain · doi:10.1093/brain/awy229 · Cited by 184
“(Jack et al., 2012) and genetically-caused Alzheimer’s disease (Bateman et al.”
Self-citationGenetic analysis of quantitative phenotypes in AD and MCI: imaging, cognition and biomarkers
Initiative, A. D. N., Shen, L., Thompson, P. M., Potkin, S. G., Bertram, L., Farrer, L. A., Foroud, T., Green, R. C., Hu, X., Huentelman, M. J., et al. (2013) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9262-z · Cited by 176
Self-citationNeuroimaging and Other Biomarkers for Alzheimer's Disease: The Changing Landscape of Early Detection
Risacher, S. L., & Saykin, A. J. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185535 · Cited by 163
Mosconi, L., Murray, J., Tsui, W. H., Li, Y., Davies, M., Williams, S., Pirraglia, E., Spector, N. C., Osorio, R. S., Glodzik, L., et al. (2014) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2014.17 · Cited by 143
Hampel, H. J., Lista, S., & Khachaturian, Z. S. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.2116 · Cited by 142
Cerebral amyloid PET imaging in Alzheimer’s disease
Jack, C. R., Barrio, J. R., & Kepe, V. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1185-7 · Cited by 137
Self-citationFunctional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease
Thomas, J. B., Brier, M. R., Bateman, R. J., Snyder, A. Z., Benzinger, T. L., Xiong, C., Raichle, M., Holtzman, D. M., Sperling, R. A., Mayeux, R., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1654 · Cited by 129
Self-citationStructural imaging biomarkers of Alzheimer's disease: predicting disease progression
Eskildsen, S. F., Coupé, P., Fonov, V., Pruessner, J. C., & Collins, D. L. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.04.034 · Cited by 129
Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration
Jack, C. R., Wiste, H. J., Knopman, D. S., Vemuri, P., Mielke, M. M., Weigand, S. D., Senjem, M. L., Gunter, J. L., Lowe, V. J., Gregg, B. E., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000386 · Cited by 129
Self-citationOlivieri, F., Capri, M., Bonafè, M., Morsiani, C., Jung, H. J., Spazzafumo, L., Viña, J., & Suh, Y. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.12.004 · Cited by 123
Franzmeier, N., Düzel, E., Jessen, F., Büerger, K., Levin, J., Duering, M., Dichgans, M., Haass, C., Suárez‐Calvet, M., Fagan, A. M., et al. (2018) · Brain · doi:10.1093/brain/awy008 · Cited by 117
Self-citationPatient-Tailored, Connectivity-Based Forecasts of Spreading Brain Atrophy
Brown, J. A., Deng, J., Neuhaus, J. M., Sible, I. J., Sias, A. C., Lee, S. E., Kornak, J., Marx, G. A., Karydas, A. M., Spina, S., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.08.037 · Cited by 116
Quantitative sodium MR imaging: A review of its evolving role in medicine
Thulborn, K. R. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.11.056 · Cited by 116
Identification of the Early Stage of Alzheimer's Disease Using Structural MRI and Resting-State fMRI
Hojjati, S. H., Ebrahimzadeh, A., & Abbas Babajani-feremi, A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00904 · Cited by 105
Data-driven modelling of neurodegenerative disease progression: thinking outside the black box
Young, A. L., Oxtoby, N. P., Garbarino, S., Fox, N. C., Barkhof, F., Schott, J. M., & Alexander, D. C. (2024) · Nature reviews. Neuroscience · doi:10.1038/s41583-023-00779-6 · Cited by 120
18 F-FDG-PET correlates of cognitive impairment in ALS
Canosa, A., Pagani, M., Cistaro, A., Montuschi, A., Iazzolino, B., Fania, P., Cammarosano, S., Ilardi, A., Moglia, C., Calvo, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002242 · Cited by 103
Rates of Decline in Alzheimer Disease Decrease with Age
Holland, D., Desikan, R. S., Dale, A. M., McEvoy, L. K., & Initiative, A. D. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042325 · Cited by 104
Irwin, D. J., Trojanowski, J. Q., & Grossman, M. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00006 · Cited by 96
Self-citationNeuro-degeneration profile of Alzheimer's patients: A brain morphometry study
Filho, S. R. B. D. S., Barbosa, J. H. O., Rondinoni, C., dos Santos, A. C., Salmón, C. E. G., Lima, N. K. D. C., Ferriolli, E., & Moriguti, J. C. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.04.001 · Cited by 102
A Systematic Review of Longitudinal Studies Which Measure Alzheimer’s Disease Biomarkers
Lawrence, E., Vegvari, C., Ower, A. K., Hadjichrysanthou, C., de Wolf, F., & Anderson, R. M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170261 · Cited by 89
ten Kate, M., Barkhof, F., Boccardi, M., Visser, P. J., Jack, C. R., Lövblad, K., Frisoni, G. B., & Scheltens, P. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.05.024 · Cited by 81
Self-citationNew evolutions in the BACE1 inhibitor field from 2014 to 2018
Hsiao, C., Rombouts, F. J. R., & Gijsen, H. J. M. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.049 · Cited by 76
Interleukin 6 Plasma Concentration Associates with Cognitive Decline: The Northern Manhattan Study
Economos, A., Wright, C. B., Moon, Y. P., Rundek, T., Rabbani, L. E., Paik, M. C., Sacco, R. L., & Elkind, M. S. V. (2013) · Neuroepidemiology · doi:10.1159/000343276 · Cited by 71
Biomarkers in pharmacology and drug discovery
Anderson, D. C., & Kodukula, K. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.026 · Cited by 72
Cavedo, E., Lista, S., Khachaturian, Z., Aisen, P., Amouyel, P., Herholz, K., Jack Jr, C. R., Sperling, R., Cummings, J., Blennow, K., et al. (2014) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2014.32 · Cited by 67
Self-citationRadiogenomics for Precision Medicine With a Big Data Analytics Perspective
Panayides, A. S., Pattichis, M. S., Leandrou, S., Pitris, C., Constantinidou, A., & Pattichis, C. S. (2019) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2018.2879381 · Cited by 66
Tang, X., Holland, D., Dale, A. M., Laurent Younes, B., Miller, M. I., & Initiative, A. D. N. (2015) · Human Brain Mapping · doi:10.1002/hbm.22758 · Cited by 67
Bertens, D., Knol, D. L., Scheltens, P., Visser, P. J., & Initiative, A. D. N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.1754 · Cited by 70
Jingami, N., Asada‐Utsugi, M., Uemura, K., Noto, R., Takahashi, M., Ozaki, A., Kihara, T., Kageyama, T., Takahashi, R., Shimohama, S., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142622 · Cited by 60
Demyelination in Mild Cognitive Impairment Suggests Progression Path to Alzheimer’s Disease
Carmeli, C., Donati, A., Antille, V., Viceic, D., Ghika, J. A., von Gunten, A., Clarke, S., Meuli, R. A., Frackowiak, R. S. J., & Knyazeva, M. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072759 · Cited by 57
Gispert, J. D., Rami, L., Sánchez‐Benavides, G., Falcón, C., Tucholka, A., Rojas, S., & Molinuevo, J. L. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.027 · Cited by 56
Lazarczyk, M. J., Hof, P. R., Bouras, C., & Giannakopoulos, P. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-127 · Cited by 55
Biomarkers for Alzheimer Dementia in Diverse Racial and Ethnic Minorities—A Public Health Priority
Barnes, L. L. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3444 · Cited by 54
Ikonomović, M. D., Mi, Z., & Abrahamson, E. E. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.11.003 · Cited by 53
A Review on Medicinal Properties of Saffron toward Major Diseases
Razak, S. I. A., Hamzah, M. S. A., Yee, F. C., Kadir, M. R. A., & Nayan, N. H. M. (2017) · Journal of Herbs Spices & Medicinal Plants · doi:10.1080/10496475.2016.1272522 · Cited by 49
Delmotte, K., Schaeverbeke, J. M., Poesen, K., & Vandenberghe, R. R. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00817-4 · Cited by 49
Murphy, K. R., Landau, S. M., Choudhury, K. R., Hostage, C. A., Shpanskaya, K. S., Sair, H. I., Petrella, J. R., Wong, T. Z., & Doraiswamy, P. M. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.04.048 · Cited by 50
The influence of APOE and TOMM40 polymorphisms on hippocampal volume and episodic memory in old age
Ferencz, B., Laukka, E. J., Lövdén, M., Kalpouzos, G., Keller, L., Graff, C., Wahlund, L., Fratiglioni, L., & Bäckman, L. (2013) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2013.00198 · Cited by 45
Staffaroni, A. M., Goh, S.-Y. M., Cobigo, Y., Ong, E., Lee, S. E., Casaletto, K. B., Wolf, A., Forsberg, L. K., Ghoshal, N., Graff-Radford, N. R., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.22847 · Cited by 41
Self-citationLongitudinal validity of PET‐based staging of regional amyloid deposition
Jelistratova, I., Teipel, S. J., & Grothe, M. J. (2020) · Human Brain Mapping · doi:10.1002/hbm.25121 · Cited by 39
Charting a path toward combination therapy for Alzheimer’s disease
Stephenson, D., Perry, D., Bens, C., Bain, L. J., Berry, D., Krams, M., Sperling, R., Dilts, D., Luthman, J., Hanna, D., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995168 · Cited by 37
Dicks, E., Vermunt, L., van der Flier, W. M., Visser, P. J., Barkhof, F., Scheltens, P., & Tijms, B. M. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101786 · Cited by 36
Gupta, V. B., Sundaram, R., & Martins, R. N. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt185 · Cited by 35
Budgeon, C. A., Murray, K., Turlach, B. A., Baker, S. A., Villemagne, V. L., Burnham, S. C., & Initiative, A. D. N. (2017) · Statistics in Medicine · doi:10.1002/sim.7300 · Cited by 33
Learning Biomarker Models for Progression Estimation of Alzheimer’s Disease
Schmidt-Richberg, A., Ledig, C., Guerrero, R., Molina‐Abril, H., Frangi, A. F., Rueckert, D., & Initiative, O. B. O. T. A. D. N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153040 · Cited by 33
Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β
Toyn, J. H., & Ahlijanian, M. K. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt244 · Cited by 31
Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)
Rombouts, F. J. R., Kusakabe, K., Hsiao, C., & Gijsen, H. J. M. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1832463 · Cited by 31
Event time analysis of longitudinal neuroimage data
Sabuncu, M. R., Bernal-Rusiel, J. L., Reuter, M., Greve, D. N., & Fischl, B. R. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.04.015 · Cited by 33
Yao, H., Zhou, B., Zhang, Z., Wang, P., Guo, Y., Shang, Y., Wang, L., Zhang, X., An, N., Liu, Y., et al. (2014) · Brain Connectivity · doi:10.1089/brain.2014.0223 · Cited by 31
Gao, N., Tao, L., Huang, J., Zhang, F., Li, X., O’Sullivan, F., Chen, S., Tian, S.-J., Mahara, G., Luo, Y., et al. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0296-1 · Cited by 30
Zhang, B., Ferman, T. J., Boeve, B. F., Smith, G. E., Maroney‐Smith, M., Spychalla, A. J., Knopman, D. S., Jack, C. R., Petersen, R. C., & Kantarci, K. (2014) · Journal of Neuroimaging · doi:10.1111/jon.12138 · Cited by 29
Self-citationData science in neurodegenerative disease: its capabilities, limitations, and perspectives
Khatami, S. G., Mubeen, S., & Hofmann‐Apitius, M. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000795 · Cited by 28
Edwards, J. D., Ramirez, J., Callahan, B. L., Tobe, S. W., OH, P. I., Berezuk, C., Lanctôt, K. L., Swardfager, W., Nestor, S. M., Kiss, A., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170238 · Cited by 29
Challenges of Integrative Disease Modeling in Alzheimer's Disease
Khatami, S. G., Robinson, C., Birkenbihl, C., Domingo‐Fernándéz, D., Hoyt, C. T., & Hofmann‐Apitius, M. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00158 · Cited by 28
Quantitative retrospective natural history modeling for orphan drug development
Garbade, S. F., Zielonka, M., Komatsuzaki, S., Kölker, S., Hoffmann, G. F., Hinderhofer, K., Mountford, W. K., Mengel, E., Sláma, T., Mechler, K., et al. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12304 · Cited by 27
Multiscale structural mapping of Alzheimer’s disease neurodegeneration
Jang, I., Li, B.-Y., Riphagen, J. M., Dickerson, B., & Salat, D. (2022) · NeuroImage: Clinical · doi:10.1016/j.nicl.2022.102948 · Cited by 27
Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27
Rombouts, F. J. R., Kusakabe, K., Alexander, R., Austin, N. E., Borghys, H., Cleyn, M. A. J. D., Dhuyvetter, D., Gijsen, H. J. M., Hrupka, B. J., Jacobs, T., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00935 · Cited by 26
Canosa, A., Calvo, A., Moglia, C., Manera, U., Vasta, R., Pede, F. D., Cabras, S., Nardo, D., Arena, V., Grassano, M., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05053-w · Cited by 25
Biomarker trajectories across stages of Alzheimer disease
Frisoni, G. B. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.81 · Cited by 25
Research and standardization in Alzheimer's trials: Reaching international consensus
Carrillo, M. C., Rowe, C. C., Szoeke, C. E. I., Masters, C. L., Ames, D. J., O’Meara, T., Macaulay, S. L., Milner, A., Ellis, K. A., Maruff, P. T., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.10.006 · Cited by 26
Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis
Andrews, K. A., Frost, C. D., Marc Modat, A., Cardoso, M. J., Rowe, C. C., Villemagne, V. L., Fox, N. C., Sebastien Ourselin, A., Schott, J. M., Rowe, C. C., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.10.013 · Cited by 23
Choi, J., Carreras, I., Aytan, N., Jenkins-Sahlin, E., Dedeoglu, A., & Jenkins, B. G. (2014) · Brain Research · doi:10.1016/j.brainres.2014.09.067 · Cited by 21
Alzheimer’s Dementia: The Emerging Role of Positron Emission Tomography
Tripathi, S. M., & Murray, A. D. (2021) · The Neuroscientist · doi:10.1177/1073858421997035 · Cited by 23
Altered Functional Network Affects Amyloid and Structural Covariance in Alzheimer’s Disease
Chang, Y., Huang, C., Chang, W., Lee, J., & Chang, C. (2018) · BioMed Research International · doi:10.1155/2018/8565620 · Cited by 20
Hampstead, B. M., Towler, S., Stringer, A. Y., & Sathian, K. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.10.007 · Cited by 22
Pérez‐Grijalba, V., Pesini, P., Monleón, I., Boada, M., Tárraga, L., Ruiz, A., Martínez‐Lage, P., José, I. S., & Sarasa, M. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121744 · Cited by 20
Parent, C., Rousseau, L., Predovan, D., Duchesne, S., & Hudon, C. (2023) · Aging Brain · doi:10.1016/j.nbas.2023.100074 · Cited by 21
Antoniano‐Villalobos, I., Wade, S., & Walker, S. G. (2014) · Journal of the American Statistical Association · doi:10.1080/01621459.2013.879061 · Cited by 18
A simulation system for biomarker evolution in neurodegenerative disease
Young, A. L., Oxtoby, N. P., Sebastien Ourselin, A., Schott, J. M., & Alexander, D. C. (2015) · Medical Image Analysis · doi:10.1016/j.media.2015.07.004 · Cited by 19
Lopresti, B. J., Royse, S. K., Mathis, C. A., Tollefson, S., & Narendran, R. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15615 · Cited by 16
Canosa, A., Vacchiano, V., D’Ovidio, F., Calvo, A., Moglia, C., Manera, U., Vasta, R., Liguori, R., Arena, V., Grassano, M., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14637 · Cited by 15
Cespedes, M. I., Fripp, J., McGree, J. M., Drovandi, C., Mengersen, K. L., & Doecke, J. D. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-012174 · Cited by 16
Insights into cognitive aging and Alzheimer’s disease using amyloid PET and structural MRI scans
Duara, R., Barker, W., Loewenstein, D., Greig, M. T., Rodriguez, R. A., Goryawala, M., Zhou, Q., & Adjouadi, M. (2015) · Clinical and Translational Imaging · doi:10.1007/s40336-015-0110-6 · Cited by 15
Detecting Alzheimer’s disease by morphological MRI using hippocampal grading and cortical thickness
Eskildsen, S. F., Pierrick Coupé, A., Fonov, V., & Collins, D. L. (2014) · Cited by 13
Deficits in recent but not lifetime familiarity in amnestic mild cognitive impairment
Anderson, N. D., Baena, E., Yang, H., & Köhler, S. (2020) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2020.107735 · Cited by 12
Apolipoprotein E and Alzheimer’s disease pathology in African American older adults
Royse, S. K., Snitz, B. E., Hill, A. V., Reese, A. C., Roush, R. E., Kamboh, M. I., Bertolet, M. H., Saeed, A., Lopresti, B. J., Villemagne, V. L., et al. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.03.005 · Cited by 10
Recent Advances in Neuroimaging Biomarkers in Geriatric Psychiatry
Khandai, A. C., & Aizenstein, H. J. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0360-9 · Cited by 10
Montgomery, K. S., Edwards, G. A., Levites, Y., Kumar, A., Myers, C. E., Gluck, M. A., Setlow, B., & Bizon, J. L. (2015) · Hippocampus · doi:10.1002/hipo.22535 · Cited by 10
Visualizing Alzheimer's disease progression in low dimensional manifolds
Seo, K., Pan, R., Lee, D., Thiyyagura, P., & Chen, K. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02216 · Cited by 10
Stephenson, D. T., Avilés, E., Bain, L. J., Brumfield, M. A., Carrillo, M. C., Comery, T. A., Compton, C. C., Corrigan, B., Gordon, M. F., Jack, C. R., et al. (2013) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479013498386 · Cited by 8
Self-citationBrain structural indicators of β-amyloid neuropathology
Jang, I., Li, B., Rashid, B., Jacoby, J. R., Huang, S. Y., Dickerson, B. C., & Salat, D. H. (2024) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2024.01.005 · Cited by 8
Müller, H., Behler, A., Landwehrmeyer, G. B., Huppertz, H., & Kassubek, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.682812 · Cited by 8
Metadata
- Authors
- Jack, C. R., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Lowe, V., Kantarci, K., Bernstein, M. A., Senjem, M. L., Gunter, J. L., Boeve, B. F., Trojanowski, J. Q., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., Knopman, D. S., & Alzheimer's Disease Neuroimaging Initiative, F. T.
- Affiliations
- Mayo Clinic (US)
- University of Pennsylvania (US)
- University of California San Diego (US)
- University of California, San Francisco (US)
- Corresponding author
- Jack, Clifford R.
- ORCID
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2012-07-01
- Volume
- 69
- Issue
- 7
- Pages
- 856-67
- ISSN
- 0003-9942 (ISSN-L)
- PMC
- PMC3595157
- OpenAlex
- W2014117421
- Cited by
- 145
- References
- 66
- Citations by year
- 2026: 12 · 2025: 3 · 2024: 7 · 2023: 2 · 2022: 3 · 2021: 7 · 2020: 17 · 2019: 6 · 2018: 9 · 2017: 10 · 2016: 9 · 2015: 11 · 2014: 20 · 2013: 23 · 2012: 6
- FWCI
- 13.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Mayo Foundation for Medical Education and Research (AG16574)
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904, R01AG11378, P50‐AG16574, U01AG06786, U01AG006786, R01AG011378, U19AG010483, R01AG041851, P50AG016574)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, biomarker trajectories, Mini-Mental State Examination, cerebrospinal fluid amyloid-beta 42, tau protein, amyloid PET, FDG-PET, hippocampal volume, apolipoprotein E, cognitive decline, amyloid-positive
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Aniline Compounds, Cognition Disorders, Cross-Sectional Studies, Female, Hippocampus, Humans, Immunoassay, Magnetic Resonance Imaging, Male, Mental Status Schedule, Peptide Fragments, Thiazoles, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Nonlinear Dynamics, Fluorodeoxyglucose F18, Positron-Emission Tomography, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
